Skip to content
Inciteful Med

The Three Types: Understanding the Differences

Last updated:

Gaucher disease is classified into three types based on brain involvement. Type 1 (95% of cases) does not affect the brain and has a good prognosis. Types 2 and 3 are neuronopathic; Type 2 is severe and fatal in infancy, while Type 3 progresses slowly with neurological symptoms like eye movement issues.

Key Takeaways

  • • Type 1 is the most common form, does not affect the brain, and allows for a near-normal life expectancy with treatment.
  • • Type 2 is a severe, acute form affecting infants that causes rapid neurological decline and is fatal in early childhood.
  • • Type 3 involves both body and brain symptoms, such as eye movement issues, but progresses much more slowly than Type 2.
  • • Current standard treatments (ERT and SRT) improve body symptoms but do not cross the blood-brain barrier to treat neurological issues.
  • • Genetic testing for mutations like N370S and L444P helps doctors predict the disease type and risk of brain involvement.

When you or your child is diagnosed with Gaucher disease, the most important distinction your medical team will make is whether the brain is involved. This is the difference between “non-neuronopathic” and “neuronopathic” disease [1].

Doctors classify the disease into three types based on the presence and speed of neurological (brain-related) symptoms. Understanding these types helps set the stage for treatment and expectations for the future [2].

Type 1: Non-Neuronopathic (95% of Cases)

Type 1 is the most common form of Gaucher disease, accounting for approximately 95% of all cases in Europe and the United States [3].

  • The Brain: Crucially, Type 1 does not involve the brain or central nervous system [3].
  • Symptoms: It primarily affects the “body” symptoms, such as an enlarged spleen and liver, low blood counts (anemia and low platelets), and bone issues [4][5].
  • Prognosis: The outlook is generally very good. With treatment, most patients live full, active lives and have a near-normal life expectancy [6][7].
  • Onset: Symptoms can appear at any age, from childhood to late adulthood [8].

Type 2: Acute Neuronopathic (The Most Severe)

Type 2 is a rare and very aggressive form of the disease that begins in early infancy, usually within the first few months of life [9][10].

  • The Brain: It is characterized by rapid and severe neurological decline [9]. Infants may have difficulty swallowing, seizures, stiff limbs, and a loss of developmental milestones [9][11].
  • Prognosis: Unfortunately, Type 2 carries a devastating prognosis. Despite medical intervention, it is typically fatal by age 2, often due to respiratory failure [10][12][11].
  • Treatment: While current treatments can help with liver or spleen symptoms, they do not stop the neurological progression [12][13].

Type 3: Chronic Neuronopathic

Type 3 is a chronic form that involves both “body” symptoms and neurological symptoms, but it progresses much more slowly than Type 2 [2][14].

  • Key Indicator: A hallmark sign of Type 3 is oculomotor apraxia—a difficulty moving the eyes quickly from side to side (horizontal gaze palsy). Patients may need to move their whole head to follow a moving object [15][16][17].
  • Progression: Other symptoms can include coordination issues, learning difficulties, or seizures that develop over time [14][18].
  • Prognosis: With treatment, many patients with Type 3 live into their 30s, 40s, or beyond [19].

The Genetic Link: Genotype and Phenotype

Your genotype (the specific mutations in your GBA1 gene) often helps doctors predict which “type” you have. This is called a genotype-phenotype correlation [20].

  • N370S: This is known as a “mild” mutation. Having at least one N370S mutation is almost always associated with Type 1 and is considered protective against brain involvement [21][22].
  • L444P: This mutation is more severe. People with two L444P mutations are at a high risk for the neurological symptoms seen in Type 2 or Type 3 [23][14].

A Note on Treatment Limitations

It is important to understand that current standard treatments—Enzyme Replacement Therapy (ERT) and Substrate Reduction Therapy (SRT)—are designed to treat the “body” symptoms (liver, spleen, blood, and bones) [24][1].

However, these medications do not cross the blood-brain barrier (BBB) effectively [25][26]. This means they can shrink an enlarged spleen in a Type 3 patient, but they cannot yet fix the eye movement or coordination issues caused by the disease in the brain [17][18]. Research is currently underway to find new therapies that can reach the brain [27][26].

Frequently Asked Questions

What is the difference between Type 1 and Type 3 Gaucher disease?
Type 1 is non-neuronopathic, meaning it does not affect the brain or central nervous system. Type 3 is a chronic neuronopathic form that involves neurological symptoms, such as eye movement difficulties and coordination issues, though it progresses much more slowly than the severe Type 2.
Does Gaucher disease affect the brain?
It depends on the specific type. Type 1, which accounts for 95% of cases, does not affect the brain. However, Type 2 and Type 3 are "neuronopathic" forms that involve the central nervous system and cause neurological symptoms like seizures or developmental delays.
What is the outlook for Type 2 Gaucher disease?
Type 2 is a rare, acute form that begins in early infancy with rapid neurological decline. Unfortunately, it carries a severe prognosis and is typically fatal by age 2, often due to respiratory failure, as current treatments cannot stop the brain-related progression.
Do current treatments help with neurological symptoms?
Standard treatments like Enzyme Replacement Therapy (ERT) and Substrate Reduction Therapy (SRT) are effective for "body" symptoms like enlarged organs and bone issues. However, they do not cross the blood-brain barrier, so they cannot currently treat the neurological symptoms found in Types 2 and 3.
How do doctors know which type of Gaucher disease I have?
Doctors assess clinical symptoms, particularly the presence and speed of brain involvement. They also look at your genotype (genetic mutations); for example, the N370S mutation is linked to Type 1, while the L444P mutation is often associated with the neuronopathic Types 2 and 3.

Questions for Your Doctor

  • • What is my (or my child’s) specific GBA1 genotype, and how does it relate to the risk of brain involvement?
  • • Can we perform a specialized eye-tracking exam to check for supranuclear gaze palsy or oculomotor apraxia?
  • • If this is a neuronopathic type (2 or 3), what extra specialists (neurology, physical therapy) should be on our team?
  • • What experimental or clinical trial treatments are available that might cross the blood-brain barrier?
  • • How often will we monitor for neurological changes, and what specific signs should I watch for at home?

Questions for You

  • • Have I noticed any unusual eye movements, like the need to move the head to help the eyes follow an object?
  • • For my child: Is they meeting developmental milestones, or have I noticed any sudden changes in their ability to swallow or move?
  • • How do I feel about the possibility of genetic testing for other family members?
  • • What are my biggest concerns about the long-term management of this condition?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Gaucher disease: A review].

    Nguyen Y, Stirnemann J, Belmatoug N

    La Revue de medecine interne 2019; (40(5)):313-322 doi:10.1016/j.revmed.2018.11.012.

    PMID: 30638965
  2. 2

    Small Bowel Mucosal Involvement and Mesenteric Mass Formation in a Young Female with Type 3 Gaucher Disease. A Case Report.

    Emanuel AJ, Holman N, Presnell SE, et al.

    Journal of gastrointestinal and liver diseases : JGLD 2018; (27(4)):459-463 doi:10.15403/jgld.2014.1121.274.bow.

    PMID: 30574629
  3. 3

    Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.

    Bennett LL, Turcotte K

    Drug design, development and therapy 2015; (9()):4639-47 doi:10.2147/DDDT.S77760.

    PMID: 26345314
  4. 4

    Pulmonary Involvement Responsive to Enzyme Replacement Therapy in an Elderly Patient with Gaucher Disease.

    Vellas D, Gramont B, Grange R, Cathébras P

    European journal of case reports in internal medicine 2021; (8(9)):002802 doi:10.12890/2021_002802.

    PMID: 34671576
  5. 5

    Insights into skeletal involvement in adult Gaucher disease: a single-center experience.

    Yoldaş Çelik M, Canda E, Yazıcı H, et al.

    Journal of bone and mineral metabolism 2025; (43(2)):166-173 doi:10.1007/s00774-024-01573-9.

    PMID: 39827430
  6. 6

    Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.

    Weinreb NJ, Camelo JS, Charrow J, et al.

    Molecular genetics and metabolism 2021; (132(2)):100-111 doi:10.1016/j.ymgme.2020.12.295.

    PMID: 33485799
  7. 7

    Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry.

    Elstein D, Belmatoug N, Bembi B, et al.

    Journal of clinical medicine 2024; (13(12)) doi:10.3390/jcm13123588.

    PMID: 38930117
  8. 8

    A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments.

    Stirnemann J, Belmatoug N, Camou F, et al.

    International journal of molecular sciences 2017; (18(2)) doi:10.3390/ijms18020441.

    PMID: 28218669
  9. 9

    Two cases of neuronopathic form of Gaucher disease - diagnostic difficulties.

    Kleinotiene G, Ivaskeviciene A, Tylki-Szymanska A

    Acta biochimica Polonica 2021; (69(1)):119-122 doi:10.18388/abp.2020_5760.

    PMID: 34905319
  10. 10

    A natural history study of pediatric patients with early onset of GM1 gangliosidosis, GM2 gangliosidoses, or gaucher disease type 2 (RETRIEVE).

    Héron B, Batzios S, Mengel E, et al.

    Orphanet journal of rare diseases 2024; (19(1)):459 doi:10.1186/s13023-024-03409-1.

    PMID: 39639297
  11. 11

    A rare cause of hydrops fetalis in two Gaucher disease type 2 patients with a novel mutation.

    Kılavuz S, Basaranoglu M, Epcacan S, et al.

    Metabolic brain disease 2022; (37(4)):1283-1287 doi:10.1007/s11011-022-00942-5.

    PMID: 35254599
  12. 12

    The natural history of type 2 Gaucher disease in the 21st century: A retrospective study.

    Roshan Lal T, Seehra GK, Steward AM, et al.

    Neurology 2020; (95(15)):e2119-e2130 doi:10.1212/WNL.0000000000010605.

    PMID: 32764102
  13. 13

    Investigation of novel pharmacological chaperones for Gaucher Disease.

    Yilmazer B, Yagci ZB, Bakar E, et al.

    Journal of molecular graphics & modelling 2017; (76()):364-378 doi:10.1016/j.jmgm.2017.07.014.

    PMID: 28763689
  14. 14

    Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia.

    Kim EA, Lim YT, Hah JO, et al.

    International journal of hematology 2019; (109(3)):361-365 doi:10.1007/s12185-018-2559-3.

    PMID: 30456712
  15. 15

    Pediatric Gaucher Disease Type 3 Presenting with Oculomotor Apraxia: A Case Report.

    Di Costanzo M, de Paulis N, Cannalire G, et al.

    Children (Basel, Switzerland) 2024; (11(8)) doi:10.3390/children11080960.

    PMID: 39201895
  16. 16

    A comprehensive monocentric ophthalmic study with Gaucher disease type 3 patients: vitreoretinal lesions, retinal atrophy and characterization of abnormal saccades.

    Hopf S, Pfeiffer N, Liesenfeld M, et al.

    Orphanet journal of rare diseases 2019; (14(1)):257 doi:10.1186/s13023-019-1244-9.

    PMID: 31727115
  17. 17

    Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt.

    Abdelwahab M, Blankenship D, Schiffmann R

    Neurology. Genetics 2016; (2(2)):e55 doi:10.1212/NXG.0000000000000055.

    PMID: 27123474
  18. 18

    Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.

    Donald A, Björkvall CK, Vellodi A, et al.

    Orphanet journal of rare diseases 2022; (17(1)):234 doi:10.1186/s13023-022-02378-7.

    PMID: 35717194
  19. 19

    Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.

    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, et al.

    Molecular genetics and metabolism 2017; (120(1-2)):47-56 doi:10.1016/j.ymgme.2016.12.001.

    PMID: 28040394
  20. 20

    A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease.

    Thirumal Kumar D, Iyer S, Christy JP, et al.

    Advances in protein chemistry and structural biology 2019; (114()):315-339 doi:10.1016/bs.apcsb.2018.10.002.

    PMID: 30635084
  21. 21

    Genotype/phenotype relationship in Gaucher disease patients. Novel mutation in glucocerebrosidase gene.

    Lepe-Balsalobre E, Santotoribio JD, Nuñez-Vazquez R, et al.

    Clinical chemistry and laboratory medicine 2020; (58(12)):2017-2024 doi:10.1515/cclm-2020-0306.

    PMID: 32589593
  22. 22

    Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

    Liu G, Boot B, Locascio JJ, et al.

    Annals of neurology 2016; (80(5)):674-685 doi:10.1002/ana.24781.

    PMID: 27717005
  23. 23

    Establishment of MUi030-A: A human induced pluripotent stem cell line carrying homozygous L444P mutation in the GBA1 gene to study type-3 Gaucher disease.

    Kangboonruang K, Pornsukjantra T, Tong-Ngam P, et al.

    Stem cell research 2023; (73()):103229 doi:10.1016/j.scr.2023.103229.

    PMID: 37890332
  24. 24

    Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.

    Zimran A, Elstein D, Gonzalez DE, et al.

    Blood cells, molecules & diseases 2018; (68()):153-159 doi:10.1016/j.bcmd.2016.10.007.

    PMID: 27839979
  25. 25

    Gaucher Disease: A Glance from a Medicinal Chemistry Perspective.

    Prencipe F, Barzan C, Savian C, et al.

    ChemMedChem 2024; (19(10)):e202300641 doi:10.1002/cmdc.202300641.

    PMID: 38329692
  26. 26

    A review on Gaucher disease: therapeutic potential of β-glucocerebrosidase-targeted mRNA/saRNA approach.

    Feng S, Rcheulishvili N, Jiang X, et al.

    International journal of biological sciences 2024; (20(6)):2111-2129 doi:10.7150/ijbs.87741.

    PMID: 38617529
  27. 27

    Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review.

    den Hollander B, Le HL, Swart EL, et al.

    Molecular genetics and metabolism 2024; (143(1-2)):108556 doi:10.1016/j.ymgme.2024.108556.

    PMID: 39116528

This guide explains the classification of Gaucher disease types for educational purposes. Your medical genetics team is the best source for determining your specific type, genotype, and prognosis.

Stay up to date

Get notified when new research about Gaucher Disease is published.

No spam. Unsubscribe anytime.